These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29623244)

  • 1. The Relationship Between Bone Mineral Density and Cardiovascular Function in Duchenne Muscular Dystrophy: A Retrospective Cohort Study.
    Kervin T; Thangarajh M
    PLoS Curr; 2018 Mar; 10():. PubMed ID: 29623244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
    Liu C; Yang DD; Zhang L; Lei XG; Jia FL; Liao Y; Chen XJ; Ning G; Luo W; Qu HB
    Front Endocrinol (Lausanne); 2022; 13():860413. PubMed ID: 35399923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
    Catalano A; Vita GL; Bellone F; Sframeli M; Distefano MG; La Rosa M; Gaudio A; Vita G; Morabito N; Messina S
    J Endocrinol Invest; 2022 Mar; 45(3):517-525. PubMed ID: 34524678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive left ventricular dysfunction and myocardial fibrosis in Duchenne and Becker muscular dystrophy: a longitudinal cardiovascular magnetic resonance study.
    Aikawa T; Takeda A; Oyama-Manabe N; Naya M; Yamazawa H; Koyanagawa K; Ito YM; Anzai T
    Pediatr Cardiol; 2019 Feb; 40(2):384-392. PubMed ID: 30564867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal health in Duchenne dystrophy: bone-size and subcranial dual-energy X-ray absorptiometry analyses.
    King WM; Kissel JT; Visy D; Goel PK; Matkovic V
    Muscle Nerve; 2014 Apr; 49(4):512-9. PubMed ID: 23893858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy.
    Jefferies JL; Eidem BW; Belmont JW; Craigen WJ; Ware SM; Fernbach SD; Neish SR; Smith EO; Towbin JA
    Circulation; 2005 Nov; 112(18):2799-804. PubMed ID: 16246949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambulatory Monitoring and Arrhythmic Outcomes in Pediatric and Adolescent Patients With Duchenne Muscular Dystrophy.
    Villa CR; Czosek RJ; Ahmed H; Khoury PR; Anderson JB; Knilans TK; Jefferies JL; Wong B; Spar DS
    J Am Heart Assoc; 2015 Dec; 5(1):. PubMed ID: 26722125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
    Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
    BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of Cardiac Dysfunction to Rhythm Abnormalities in Patients With Duchenne or Becker Muscular Dystrophies.
    Chiang DY; Allen HD; Kim JJ; Valdes SO; Wang Y; Pignatelli RH; Lotze TE; Miyake CY
    Am J Cardiol; 2016 Apr; 117(8):1349-54. PubMed ID: 26952271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy.
    Schade van Westrum SM; Hoogerwaard EM; Dekker L; Standaar TS; Bakker E; Ippel PF; Oosterwijk JC; Majoor-Krakauer DF; van Essen AJ; Leschot NJ; Wilde AA; de Haan RJ; de Visser M; van der Kooi AJ
    Neurology; 2011 Jul; 77(1):62-6. PubMed ID: 21700587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystrophy.
    Olivieri LJ; Kellman P; McCarter RJ; Cross RR; Hansen MS; Spurney CF
    J Cardiovasc Magn Reson; 2016 Oct; 18(1):72. PubMed ID: 27788681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy.
    Ronsley R; Islam N; Kang M; Nadel H; Reilly C; Metzger D; Selby K; Panagiotopoulos C
    Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420972400. PubMed ID: 33335437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of swallowing dysfunction in Becker muscular dystrophy and Duchenne muscular dystrophy.
    Yamada Y; Kawakami M; Wada A; Otsuka T; Muraoka K; Liu M
    Disabil Rehabil; 2018 Jun; 40(12):1421-1425. PubMed ID: 28288529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
    Houston C; Mathews K; Shibli-Rahhal A
    Muscle Nerve; 2014 Apr; 49(4):506-11. PubMed ID: 23835890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy.
    Annexstad EJ; Bollerslev J; Westvik J; Myhre AG; Godang K; Holm I; Rasmussen M
    Int J Pediatr Endocrinol; 2019; 2019():4. PubMed ID: 31889957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
    Hawker GA; Ridout R; Harris VA; Chase CC; Fielding LJ; Biggar WD
    Arch Phys Med Rehabil; 2005 Feb; 86(2):284-8. PubMed ID: 15706555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.